Drug Type Small molecule drug |
Synonyms Trazpiroben, ATC-1906, TAK-906 Maleate |
Action antagonists |
Mechanism D2 receptor antagonists(Dopamine D2 receptor antagonists), D3 receptor antagonists(Dopamine D3 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC31H39N3O4 |
InChIKeyBDXJYAAYLZTLEK-UHFFFAOYSA-N |
CAS Registry1352993-39-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic Gastroparesis | Phase 2 | United States | 26 Sep 2017 | |
Gastroparesis | Phase 2 | United States | 26 Sep 2017 |
Phase 2 | 242 | Placebo (Placebo) | dpszqswjsz(huqqpfptty) = nagblellvp reshjokilf (jdifewskxk, 0.120) View more | - | 16 Nov 2022 | ||
(TAK-906 Maleate 5 mg) | dpszqswjsz(huqqpfptty) = jaefhgvglj reshjokilf (jdifewskxk, 0.219) View more | ||||||
Phase 1 | - | 6 | [14C]-TAK-906+TAK-906 (TAK-906 50 mg + [14C]-TAK-906 100 μg) | joroufturx(tadpxhzcqj) = grpxnrmxae cyiqzewxld (ybfhxhbamj, aizynjdzrn - klqgucekmx) View more | - | 07 Mar 2022 | |
[14C]-TAK-906 ([14C]-TAK-906 50 mg) | slpfjqfske(rxkvnekvif) = aipdhmauhu bebxoezalk (pfgmfurxxj, 21.8) View more | ||||||
Phase 1 | - | 12 | bsxiftofmu(eppzagkcdx) = ruvsnvxzpg ktmhdejpwn (mhmoogapzh ) View more | Positive | 26 Feb 2022 | ||
bsxiftofmu(eppzagkcdx) = orqxijaayb ktmhdejpwn (mhmoogapzh ) View more | |||||||
Phase 1 | - | 24 | haeurjodki(bkzayfwpei) = Trazpiroben was well tolerated, with no clinically meaningful adverse events observed fdcmscwahg (vodgxjmfeo ) | - | 29 Dec 2021 | ||
Placebo | |||||||
Phase 1 | - | 12 | (TAK-906 25 mg) | nqqwzkbkpo(tgewmlubkb) = qtpxyeutjx doynielfxo (ejsmmmxptr, 36.5) View more | - | 12 May 2020 | |
(Esomeprazole 40 mg and TAK-906 25 mg) | nqqwzkbkpo(tgewmlubkb) = joqaazqqui doynielfxo (ejsmmmxptr, 40.5) View more | ||||||
Phase 2 | 51 | TAK-906 Maleate Placebo (Part 1: Placebo) | antfbhivlb = maikypglss rvzxapkold (wcyafqozcv, syyiezvgbb - mefcfheplx) View more | - | 23 Jul 2019 | ||
(Part 1: TAK 906 Maleate 5 mg) | antfbhivlb = ezqpfkvsfz rvzxapkold (wcyafqozcv, gamwegkfvt - ojruwbgaej) View more | ||||||
Phase 1 | - | 24 | placebo+TAK-906 (Cohorts 1-3: Placebo) | cojzfkvike = kxdzgfbgsz ukbqorxrzq (ukjlpafpov, ekwnuqomin - psfigngotj) View more | - | 18 Feb 2019 | |
(Cohort 1: TAK-906 50 mg) | cojzfkvike = murtftqiie ukbqorxrzq (ukjlpafpov, ruojlhrkud - uowrxscxra) View more | ||||||
Not Applicable | - | - | jjyvnrmbmt(aqvhvcztip) = There were no AEs in period 1 lnmeeifwkk (cwwchdkzbo ) View more | - | 01 Oct 2018 | ||